Telmisartan in treatment of hypertension Review article
Article Sidebar
Main Article Content
Abstract
Blockade of the renin–angiotensin–aldosterone system is one of the basic mechanisms of the treatment of hypertension and prevention of its complications. Telmisartan is a drug which registration includes not only the treatment of hypertension in adults but also its use in order to reduce the burden of cardiovascular disease in patients with manifest atherosclerotic disease. At the same time optimal pharmacokinetic parameters allow achieving a 24-hour blood pressure control.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Wienen W., Hauel N., Van Meel J.C. et al.: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. British Journal of Pharmacology 1993; 110(1): 245-252.
3. Timmermans P.B.: Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertension Research: official journal of the Japanese Society of Hypertension 1999; 22(2): 147-153.
4. Neutel J.M.: Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker – telmisartan. Blood Pressure Supplement 2001; 1: 27-32.
5. ONTARGET Investigators; Yusuf S., Teo K.K., Pogue J. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358(15): 1547-1559.
6. Barnett A.H., Bain S.C., Bouter P. et al.: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N. Engl. J. Med. 2004; 351(19): 1952-61.
7. Schmieder R.E., Delles C., Mimran A. et al.: Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care 2007; 30(6): 1351-1356.
8. Galzerano D., Tammaro P., del Viscovo L. et al.: Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. American Journal of Hypertension 2005; 18(12 Pt 1): 1563-1569.
9. Petrovic I., Petrovic D., Vukovic N. et al.: Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin- converting enzyme inhibitor ramipril in hypertensive patients. The Journal of International Medical Research 2005; 33(supl. 1): 39A-49A.
10. Benson S.C., Pershadsingh H.A., Ho C.I. et al.: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma- modulating activity. Hypertension 2004; 43(5): 993-1002.
11. Amano Y., Yamaguchi T., Ohno K. et al.: Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertension Research: Official Journal of the Japanese Society of Hypertension 2012; 35(7): 715-719.
12. Vitale C., Mercuro G., Castiglioni C. et al.: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology 2005; 4: 6.
13. Nagel J.M., Wang X., Lewis J.D. et al.: Atmospheric CO2 enrichment alters energy assimilation, investment and allocation in Xanthium strumarium. The New Phytologist 2005; 166(2): 513-523.
14. Miura Y., Yamamoto N., Tsunekawa S. et al.: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28(3): 757-758.
15. Sharma A.M., Davidson J., Koval S., Lacourciere Y.: Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovascular Diabetology 2007; 6: 28.
16. Grabowski M.: Próba pozycjonowania trzech leków hipotensyjnych: ramiprilu, telmisartanu i walsartanu w leczeniu nadciśnienia tętniczego w zależności od ciśnienia tętniczego i ryzyka sercowo-naczyniowego. Medycyna Faktów 2012; 4(17): 39-47.